Neuren Pharmaceuticals Ltd has released a press release.
2019 year-end update and 2020 outlook
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Patent to 2034 granted in Europe for Neurens NNZ-2591
- Phase 3 trial of trofinetide in Rett syndrome commences
- FDA Grants Orphan Drug Designation for Neuren's NNZ-2591 to Treat Angelman, Phelan-McDermid and Pitt Hopkins Syndromes
- FDA grants Orphan for both Phelan-McDermid and Pitt Hopkins
- FDA grants Orphan Drug Designation for NNZ-2591 in Angelman
Later from Neuren Pharmaceuticals
- Update on trofinetide Phase 3 trial in Rett syndrome
- Appendix 4E and 2019 full year accounts
- Rare Pediatric Disease designation received from FDA
- Commentary on potential benefit to Neuren of RPD designation
- Compelling results for 2591 dose ranging study in PMS model
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals